Wedbush Reiterates Neutral on Regenxbio, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides has reiterated a Neutral rating on Regenxbio (NASDAQ:RGNX) and maintained a $20 price target.
October 05, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst maintains a Neutral rating and a $20 price target on Regenxbio.
The news is directly about Regenxbio and its rating by Wedbush. The Neutral rating suggests that the analyst does not expect significant price movement in the short term. The maintained price target of $20 also indicates that the analyst's valuation of the company has not changed.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100